Based on the analysis of Microbot Medical's profitability, liquidity, and operating efficiency, Microbot Medical is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December. At this time, Microbot Medical's Net Tangible Assets are comparatively stable compared to the past year. Property Plant Equipment is likely to gain to about 1.2 M in 2024, whereas Other Current Liabilities is likely to drop slightly above 2.6 M in 2024. Key indicators impacting Microbot Medical's financial strength include:
The financial analysis of Microbot Medical is a critical element in measuring its lifeblood. Investors should not minimize Microbot Medical's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(11.28 Million)
Microbot
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Dividend Yield
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Operating Cycle
Cash Conversion Cycle
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Stock Based Compensation
Dividends Paid
Sale Purchase Of Stock
Change To Inventory
Change To Account Receivables
Investments
Change Receivables
Net Borrowings
Total Cashflows From Investing Activities
Exchange Rate Changes
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Change To Operating Activities
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Short Term Debt
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Common Stock Total Equity
Common Stock
Short Term Investments
Intangible Assets
Current Deferred Revenue
Good Will
Inventory
Net Tangible Assets
Long Term Debt
Retained Earnings Total Equity
Long Term Debt Total
Capital Surpluse
Deferred Long Term Liab
Non Current Liabilities Other
Property Plant Equipment
Capital Lease Obligations
Other Assets
Preferred Stock Total Equity
Other Liab
Short Long Term Debt
Net Invested Capital
Net Working Capital
Capital Stock
Depreciation And Amortization
Interest Expense
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Research Development
Selling General Administrative
Selling And Marketing Expenses
Net Income From Continuing Ops
Non Operating Income Net Other
Net Income Applicable To Common Shares
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Microbot Medical Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Microbot Medical's financial statements are interrelated, with each one affecting the others. For example, an increase in Microbot Medical's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Microbot Medical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Microbot Medical. Check Microbot Medical's Beneish M Score to see the likelihood of Microbot Medical's management manipulating its earnings.
Microbot Medical Stock Summary
Microbot Medical competes with Heartbeam, EUDA Health, Nutex Health, Healthcare Triangle, and Mangoceuticals, Common. Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts. Microbot Medical operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 20 people.
The reason investors look at the income statement is to determine what Microbot Medical's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Microbot Medical's current stock value. Our valuation model uses many indicators to compare Microbot Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Microbot Medical competition to find correlations between indicators driving Microbot Medical's intrinsic value. More Info.
Microbot Medical is regarded fourth in return on equity category among its peers. It also is regarded fourth in return on asset category among its peers . At this time, Microbot Medical's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Microbot Medical by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Microbot Medical Systematic Risk
Microbot Medical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Microbot Medical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Microbot Medical correlated with the market. If Beta is less than 0 Microbot Medical generally moves in the opposite direction as compared to the market. If Microbot Medical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Microbot Medical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Microbot Medical is generally in the same direction as the market. If Beta > 1 Microbot Medical moves generally in the same direction as, but more than the movement of the benchmark.
Microbot Medical Thematic Clasifications
Microbot Medical is part of several thematic ideas from Office Supplies to Drugs. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Microbot Medical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Microbot Medical's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Microbot Medical growth as a starting point in their analysis.
Microbot Medical November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Microbot Medical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Microbot Medical. We use our internally-developed statistical techniques to arrive at the intrinsic value of Microbot Medical based on widely used predictive technical indicators. In general, we focus on analyzing Microbot Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Microbot Medical's daily price indicators and compare them against related drivers.
When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.